Original language | English (US) |
---|---|
Pages (from-to) | 951-955 |
Number of pages | 5 |
Journal | Cancer Communications |
Volume | 43 |
Issue number | 8 |
DOIs | |
State | Published - Aug 2023 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Cancer Communications, Vol. 43, No. 8, 08.2023, p. 951-955.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Single-cell transcriptomic analysis uncovers intratumoral heterogeneity and drug-tolerant persister in ALK-rearranged lung adenocarcinoma
AU - Kwok, Hoi Hin
AU - Li, Huiyu
AU - Yang, Jiashuang
AU - Deng, Junyang
AU - Lee, Nerissa Chui Mei
AU - Au, Timmy Wing Kuk
AU - Sit, Alva Ko Yung
AU - Hsin, Michael Kuan Yew
AU - Ma, Stephanie Kwai Yee
AU - Cheung, Lydia Wai Ting
AU - Girard, Luc
AU - Fujimoto, Junya
AU - Wistuba, Ignacio Ivan
AU - Gao, Boning
AU - Minna, John Dorrance
AU - Lam, David Chi Leung
N1 - Funding Information: The research work described in this report was supported by the Lee and the Ho Families Respiratory Research Fund (research donation to DCL). National Natural Science Foundation of China (Grant# 82022078 to LWTC). United States National Cancer Institute Lung Cancer Specialized Program in Research Excellence (SPORE) P50 (CA070907 to JDM). Funding Information: The research work described in this report was supported by the Lee and the Ho Families Respiratory Research Fund (research donation to DCL). National Natural Science Foundation of China (Grant# 82022078 to LWTC). United States National Cancer Institute Lung Cancer Specialized Program in Research Excellence (SPORE) P50 (CA070907 to JDM). Not applicable.
PY - 2023/8
Y1 - 2023/8
UR - http://www.scopus.com/inward/record.url?scp=85161438790&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85161438790&partnerID=8YFLogxK
U2 - 10.1002/cac2.12449
DO - 10.1002/cac2.12449
M3 - Letter
C2 - 37272226
AN - SCOPUS:85161438790
SN - 1000-467X
VL - 43
SP - 951
EP - 955
JO - Cancer Communications
JF - Cancer Communications
IS - 8
ER -